This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koenig, W. Search for Related Content PubMed PubMed Citation Articles by Koenig, W. Related Collections Risk Factors Imaging Epidemiology Related Article

(Circulation. 2007;116:3-5.)
© 2007 American Heart Association, Inc.

Editorial

Cardiovascular Biomarkers

Added Value With an Integrated Approach?

Wolfgang Koenig, MD, FRCP, FESC

From the Department of Internal Medicine II, Cardiology, University of Ulm Medical Center, Ulm, Germany.

Correspondence to Wolfgang Koenig, MD, Department of Internal Medicine II, Cardiology, University of Ulm Medical Center, Robert-Koch Str 8, D-89081 Ulm, Germany. E-mail wolfgang.koenig@uniklinik-ulm.de

Key Words: Editorials • atherosclerosis • epidemiology • imaging • inflammation • risk factors

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
In primary prevention, traditional risk factors are a useful first step in the determination of who could be at risk for cardiovascular events. In the era of "global risk assessment" scores such as the Framingham score, the Prospective Cardiovascular Münster (PROCAM) score, or the European Society of Cardiology Systematic Coronary Risk Evaluation (SCORE), which are derived from multivariable statistical models, should be used.¹ However, it has been noted that a considerable number of at-risk patients cannot be identified on the basis of traditional risk factors alone.² This has prompted the search for novel markers of cardiovascular risk to help improve risk prediction.³ Such markers could either represent various blood biomarkers relevant to the pathophysiology of atherothrombosis (eg, markers of the inflammatory response, coagulation markers, markers of platelet aggregation, lipoproteins, or lipid-related variables), genetic markers, or markers of subclinical disease, which may also aid in improved risk prediction. Determination of global risk on the basis of traditional risk factors allows categorization into high (10-year risk, >20%), low (10-year risk, <10%), or intermediate risk (10-year risk, 10% to 20%). Subjects at high risk should be recommended lifestyle changes or prescribed a statin. Subjects at low risk would be reevaluated 3 to 5 years later. Those at intermediate risk, however, who comprise up to 40% of the population at risk,⁴ would be candidates for additional testing to increase or decrease their actual risk. A large panel of blood biomarkers are available for this purpose, but most of them are not yet applicable in . . . [Full Text of this Article]

Related Article:

Issue Highlights
Circulation 2007 116: 1. [Extract] [Full Text]

This article has been cited by other articles:

				R. S. Rosenstein and D. Parra Biomarkers for Prediction of Cardiovascular Events JAMA, November 18, 2009; 302(19): 2089 - 2090. [Full Text] [PDF]

				D. I. Buckley, R. Fu, M. Freeman, K. Rogers, and M. Helfand C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the U.S. Preventive Services Task Force Ann Intern Med, October 6, 2009; 151(7): 483 - 495. [Abstract] [Full Text] [PDF]

				F. Addabbo, B. Ratliff, H.-C. Park, M.-C. Kuo, Z. Ungvari, A. Ciszar, B. Krasnikof, K. Sodhi, F. Zhang, A. Nasjletti, et al. The Krebs Cycle and Mitochondrial Mass Are Early Victims of Endothelial Dysfunction: Proteomic Approach Am. J. Pathol., January 1, 2009; 174(1): 34 - 43. [Abstract] [Full Text] [PDF]